Why Is TEMPUS AI INC A (TEM) Stock Down Today?

Tempus AI Inc A (TEM) fell 7.35% to $67.35 in early trading on August 24, 2026, marking one of the stock's sharpest intraday declines in recent months. The drop followed a series of recent insider sales and a mixed market reaction to the company's latest FDA clearance for its AI-based pulmonary hypertension detection tool. Despite regulatory progress, the stock has faced pressure amid heavy insider selling and a broader market environment that has weighed on high-beta technology names.

What Happened

Tempus AI received FDA 510(k) clearance for its ECG-PH software, which is designed to detect signs of pulmonary hypertension from standard electrocardiograms. The clearance expands the company's portfolio of cardiovascular AI tools and highlights its ongoing efforts to integrate artificial intelligence into diagnostic medicine. However, the news was not enough to offset investor concerns. Over the past 90 days, insiders have sold a total of $47.5 million in shares, with 18 separate sales reported. On August 18, the CEO of Tempus AI and other top executives executed sales, signaling a shift in ownership strategy. Additionally, a Tempus director had sold stock four days before a 24% rally in the stock earlier in the year, raising questions about timing and confidence.

What The Data Shows

The stock opened at $70.97, a 2.4% gap down from the prior close, and continued to fall throughout the session, hitting a low of $67.14 before stabilizing slightly. The volume of 3.6 million shares is 0.6 times the 3-month daily average, indicating moderate participation. Over the past 52 weeks, the stock has traded between $40.77 and $104.32. The company remains unprofitable, with a trailing twelve-month EPS of -1.43 and a net margin of -17.8%. Despite a 50.4% year-over-year revenue increase, the stock's high beta of 3.58 makes it particularly sensitive to market volatility. On the options front, a notable $5.4 million call premium was printed in the last 36 hours, suggesting some speculative interest. The 52-week tape also showed the stock printing one fresh 52-week low on the same day as the clearance announcement.

What To Watch

The stock has no upcoming earnings report on the calendar, but investors will continue to monitor the breadth of coverage and sentiment shifts. With insider selling remaining a key focus, any new Form 4 filings or unusual options activity could influence near-term direction.